Journal of Parkinson's disease最新文献

{"title":"The impact of motor, non-motor, and social aspects on the sexual health of women living with Parkinson's disease.","authors":"Kátia Cirilo Costa Nóbrega, Isaíra Almeida Pereira da Silva Nascimento, Bruno Rafael Antunes Souza, Raíssa Amorim Gonçalves, Thalyta Silva Martins, Geovanna Ferreira Santos, Bruno Eron de Almeida da Silva, André Helene Frazão, Antônio Carlos Roque, Rodolfo Savica, Maria Elisa Pimentel Piemonte","doi":"10.1177/1877718X251315375","DOIUrl":"https://doi.org/10.1177/1877718X251315375","url":null,"abstract":"<p><strong>Background: </strong>Sexual health is influenced by a complex interplay of biological, psychological, and social factors, all of which can be impacted by Parkinson's disease (PD). Female sexual dysfunction includes reduced sexual desire and/or arousal, pain during sexual activity, or difficulty achieving orgasm. Despite its impact on quality of life, sexual health in women with PD remains poorly understood.</p><p><strong>Objective: </strong>To investigate the impact of motor, non-motor, and social PD aspects on sexual health of women with PD.</p><p><strong>Methods: </strong>We conducted a cross-sectional study with 100 women with PD (Hoehn and Yahr stages 1-3) who reported an active sex life in the last six months. Data were collected via remote interviews and included demographic and clinical features, cognitive capacity, motor and non-motor experiences, fatigue, self-esteem, sleep disorders, couple relationship quality, depressive symptoms, and sexual health assessments using the Female Sexual Function Index (FSFI) and Sexual Quotient-Female (SQ-F). Multiple regression models were used to identify predictors of FSFI and SQ-F scores.</p><p><strong>Results: </strong>Results indicated that while several motor, non-motor, and social factors correlated with sexual health, only couple relationship quality and sleep quality significantly predicted both short-term (FSFI) and long-term (SQ-F) sexual health. No significant associations were observed with age, disease onset, postmenopausal status, or daily medication dosage.</p><p><strong>Conclusions: </strong>The present study's evidence identifies multiple key areas, such as couple's relationship quality and sleep quality that could be targeted for intervention to improve sexual health in women with PD.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X251315375"},"PeriodicalIF":4.0,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143492389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving reliability of movement assessment in Parkinson's disease using computer vision-based automated severity estimation.","authors":"Jinyu Xu, Xin Xu, Xudong Guo, Zezhi Li, Boya Dong, Chen Qi, Chunhui Yang, Dong Zhou, Jiali Wang, Lu Song, Ping He, Shanshan Kong, Shuchang Zheng, Sichao Fu, Wei Xie, Xuan Liu, Ya Cao, Yilin Liu, Yiqing Qiu, Zhiyuan Zheng, Fei Yang, Jing Gan, Xi Wu","doi":"10.1177/1877718X241312605","DOIUrl":"https://doi.org/10.1177/1877718X241312605","url":null,"abstract":"<p><strong>Background: </strong>Clinical assessments of motor symptoms rely on observations and subjective judgments against standardized scales, leading to variability due to confounders. Improving inter-rater agreement is essential for effective disease management.</p><p><strong>Objective: </strong>We developed an objective rating system for Parkinson's disease (PD) that integrates computer vision (CV) and machine learning to correct potential discrepancies among raters while providing the basis for model performance to gain professional acceptance.</p><p><strong>Methods: </strong>A prospective PD cohort (n = 128) were recruited from multi-centers. Motor examination videos were recorded using an android tablet with CV-based software following the MDS-UPDRS Part-III instructions. Videos included facial, upper- and lower-limb movements, arising from a chair, standing, and walking. Fifteen certified clinicians were recruited from multi-centers. For each video, five clinicians were randomly selected to independently rate the severity of motor symptoms, validate the videos and movement variables (MovVars). Machine learning algorithms were applied for automated rating and feature importance analysis. Inter-rater agreement among human raters and the agreement between artificial intelligence (AI)-generated ratings and expert consensus were calculated.</p><p><strong>Results: </strong>For all validated videos (n = 1024), AI-based ratings showed an average absolute accuracy of 69.63% and an average acceptable accuracy of 98.78% against the clinician consensus. The mean absolute error between the AI-based scores and clinician consensus was 0.32, outperforming the inter-rater variability (0.65), potentially due to the combined utilization of diverse MovVars.</p><p><strong>Conclusions: </strong>The algorithm enabled accurate video-based evaluation of mild motor symptom severity. AI-assisted assessment improved the inter-rater agreement, demonstrating the practical value of CV-based tools in screening, diagnosing, and treating movement disorders.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X241312605"},"PeriodicalIF":4.0,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Saccade, pupil, and blink abnormalities in prodromal and manifest alpha-synucleinopathies.","authors":"Maha Habibi, Brian C Coe, Donald C Brien, Jeff Huang, Heidi C Riek, Frank Bremmer, Lars Timmermann, Annette Janzen, Wolfgang H Oertel, Douglas P Munoz","doi":"10.1177/1877718X241308193","DOIUrl":"https://doi.org/10.1177/1877718X241308193","url":null,"abstract":"<p><strong>Background: </strong>Saccade, pupil, and blink control are impaired in patients with α-synucleinopathies (αSYN): Parkinson's disease (PD) and multiple system atrophy (MSA). Isolated REM (rapid eye movement) Sleep Behavior Disorder (iRBD) is a prodromal stage of PD and MSA and a prime candidate for investigating early oculo-pupillo-motor abnormalities that may precede or predict conversion to clinically manifest αSYN.</p><p><strong>Objective: </strong>Determine whether saccade, pupil, and blink responses in iRBD are normal or similar to those identified in PD and MSA.</p><p><strong>Methods: </strong>Video-based eye-tracking was conducted with 68 patients with iRBD, 49 with PD, 17 with MSA, and 95 healthy controls (CTRL) performing an interleaved pro-/anti-saccade task that probed sensory, motor, and cognitive processes involved in eye movement control.</p><p><strong>Results: </strong>Horizontal saccade and blink behavior was intact in iRBD, but abnormal in PD and MSA. iRBD patients, however, demonstrated reduced pupil dilation size, which closely resembled the changes found in PD and MSA. In the iRBD group, the extent of these pupillary changes appeared to correlate with the degree of hyposmia and reduction in dopamine transporter imaging signal.</p><p><strong>Conclusions: </strong>Pupil abnormalities were present in iRBD, but blink and horizontal saccade responses were intact. Future longitudinal studies are required to determine which prodromal pupil abnormalities predict conversion from iRBD to PD or MSA and to identify the time window, in relation to conversion, when horizontal saccade responses become abnormal.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X241308193"},"PeriodicalIF":4.0,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A perspective of persons with Parkinson's disease on the contribution of alpha-synuclein seed amplification assay biomarker to the diagnosis of Parkinson's disease.","authors":"Susanne Bowen, David Blacker, Richard Prettyman","doi":"10.1177/1877718X251315651","DOIUrl":"https://doi.org/10.1177/1877718X251315651","url":null,"abstract":"<p><p>Alpha-synuclein is a normal protein, but misfolded forms in the cerebrospinal fluid can be detected using the alpha-synuclein seed amplification assay (αSyn-SAA), a potential biomarker for Parkinson's disease (PD). Some experts consider this assay a 'game changer' for redefining and reclassifying PD. In this article, we, three individuals with PD, share our perspective on the suitability of αSyn-SAA as the basis for a new classification and staging system for PD. We also discuss other biomarkers and their relevance to those with PD, drawing on our research and the scientific background of two authors. We aim to clarify complex media reports and study findings for the PD community. We argue that while αSyn-SAA can identify the presence of pathology, it cannot explain the underlying cause for such pathology or predict the progression of PD. Given the varied biological pathways leading to PD, using αSyn-SAA as a unified biological definition for a new classification system is premature. Further research is needed before it can serve as the foundation for defining and staging Parkinson's disease. Although αSyn-SAA has its place, like the DAT scan, it should be seen as a tool for confirming diagnoses rather than defining them.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X251315651"},"PeriodicalIF":4.0,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological definitions of synucleinopathies should be anchored in clinical trajectories and encompass the complex biology of the disease.","authors":"David Bendetowicz, Vincent Planche, Erwan Bezard, Benjamin Dehay, Wassilios G Meissner","doi":"10.1177/1877718X241313443","DOIUrl":"https://doi.org/10.1177/1877718X241313443","url":null,"abstract":"<p><p>Recently, two proposals for defining Parkinson's disease and its related pathogenic processes have been published. In this viewpoint, we discuss the primary drivers behind these efforts, the future directions, and the challenges that must be addressed. While finding biomarkers is a mandatory step for better precision medicine and optimal patient stratification in therapeutic trials, we argue that a biological definition of Parkinson's disease based on a single biomarker will struggle to account for the complexity of the mechanisms involved in developing the disease. Additionally, a biological definition of asymptomatic patients should rely on a thorough understanding of patients' clinical trajectories, which is currently not the case in synucleinopathies.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X241313443"},"PeriodicalIF":4.0,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduced volume of the mediodorsal and anteroventral thalamus is associated with anxiety in Parkinson's disease: A cross-sectional 7-tesla MRI study.","authors":"Guillaume Carey, Mark L Kuijf, Stijn Michielse, Amée F Wolters, Kathy Dujardin, Albert Fg Leentjens","doi":"10.1177/1877718X241308141","DOIUrl":"https://doi.org/10.1177/1877718X241308141","url":null,"abstract":"<p><strong>Background: </strong>Parkinson's disease (PD)-related anxiety occurs frequently and may be associated with imbalance between anxiety-related circuits. While the thalamus is a shared region of these circuits, its role in PD-related anxiety has not been explored so far.</p><p><strong>Objective: </strong>To identify changes in volume of the thalamus and its subnuclei in patients with PD-related anxiety.</p><p><strong>Methods: </strong>Cognitively intact PD patients (n = 105) were divided into two groups based on their score on the Parkinson anxiety scale (PAS): 31 PD patients had anxiety (Anx-PD) and 74 did not have anxiety (non-Anx-PD). Forty-five healthy control subjects were included. Participants underwent 7-Tesla MRI scanning. Using automatic segmentation, the volumes of the thalamus and its subnuclei were measured, compared between the groups and regressed on the PAS.</p><p><strong>Results: </strong>The volumes of the thalamus and its subnuclei did not significantly differ between the groups. However, in anxious PD patients, more severe anxiety was strongly associated with a smaller volume of the right medial thalamic subregion, specifically the right mediodorsal magnocellular nucleus and the right mediodorsal parvocellular nucleus (R = 0.63, ß_PAS= -0.546, p-value_model= 0.007 and R = 0.60, ß_PAS= -0.547, p-value_model= 0.016, respectively), and of the left anteroventral thalamus (R = 0.73, FDR p-value_model= 0.002, ß_PAS= -0.407, p-value_PAS= 0.01).</p><p><strong>Conclusions: </strong>A reduced volume of the mediodorsal and anteroventral thalamus, overlapping structures between the anxiety related circuits, are associated with more severe PD-related anxiety and may explain its high prevalence in the disease.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X241308141"},"PeriodicalIF":4.0,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psilocybin-assisted psychotherapy for Parkinson's disease without depression: A case-report.","authors":"Vanessa Fleury, Emilie Tomkova, Sabina Catalano Chiuvé, Louise Penzenstadler","doi":"10.1177/1877718X241312604","DOIUrl":"https://doi.org/10.1177/1877718X241312604","url":null,"abstract":"<p><strong>Background: </strong>Psychedelic assisted psychotherapy (PAP) can improve treatment-resistant depression. Its usefulness in Parkinson's disease (PD) is unknown. PD patients may have problems adjusting to their chronic progressive neurological disease. A change from emotional avoidance to acceptance has been reported following psilocybin administration in patients with treatment-resistant depression.</p><p><strong>Objective: </strong>To report for the first time the effect of psilocybin in a PD patient.</p><p><strong>Methods: </strong>A non-depressed 43-year-old female with a 2-year history of PD presented with difficulty adjusting to PD, anxious ruminations and pessimism. The patient declined an increase in dopaminergic medication or the introduction of an anxiolytic. Therapeutic patient education was not beneficial. The patient received four sessions of high-dose PAP within one year. Neurological and psychiatric assessments were performed before and at one year follow-up using qualitative interviews and quantitative assessment of motor status, dispositional optimism, depression, anxiety, apathy, and well-being.</p><p><strong>Results: </strong>PAP was well tolerated. It significantly improved the patient's overall pessimistic outlook on her future and decreased her anxious ruminations and worries about potential handicap due to PD. Her general well-being improved, as well as all psychometric scores except for the apathy scale. Motor status remained unchanged. Better acceptance of PD allowed her to accept pharmacological treatment adjustment.</p><p><strong>Conclusions: </strong>PAP could be a safe and useful treatment for PD patients with dispositional pessimism and difficulties accepting their disease by promoting profound decentration from habitual thoughts and emotions, improving mood and PD acceptance. Randomized, controlled studies are needed to confirm this result.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X241312604"},"PeriodicalIF":4.0,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cortical α4β2-nicotinic acetylcholine receptors and cognitive decline in Parkinson's disease.","authors":"Kelly A Mills, Hiroto Kuwabara, Yong Du, Gabriela Gomez, Chelsie S Motley, Yana Skorobogatova, Ergi Spiro, Jennifer M Coughlin, Wojciech Lesniak, Jason Brandt, Vidya Kamath, Martin G Pomper, Gwenn S Smith","doi":"10.1177/1877718X241313373","DOIUrl":"10.1177/1877718X241313373","url":null,"abstract":"<p><strong>Background: </strong>Autopsy and <i>in vivo</i> molecular imaging studies suggest altered binding of the α4β2-nicotinic cholinergic receptor (α4β2-nAChR) with cognitive dysfunction in Parkinson's disease (PD).</p><p><strong>Objective: </strong>To determine the relationship between cortical and hippocampal binding of the α4β2-nAChR with [¹⁸F]XTRA PET, a high-affinity radiotracer that enables quantification of α4β2-nAChR in these regions, and cognitive function in individuals with PD.</p><p><strong>Methods: </strong>Individuals with PD (N = 32) and age-similar, controls without PD or dementia (N = 10) completed a cognitive assessment and one 90-min, [¹⁸F]XTRA PET scan. Metabolite-corrected arterial input function radioactivity time-activity curves were generated to obtain total distribution volume (V_T) across 12 regions of interest (ROIs). [¹⁸F]XTRA binding was compared 1) between controls and people with PD and 2) between controls, persons with PD with normal cognition (PD-NC), and persons with PD with MCI (PD-MCI).</p><p><strong>Results: </strong>[¹⁸F]XTRA binding was higher in the occipital cortex of the combined group of PD participants compared to age-similar controls. No regions showed lower binding in PD. V_T with, but not without, partial volume correction was different between controls, PD-NC, and PD-MCI groups, and this was driven by higher binding in PD-MCI compared to controls. Regression of regional V_T on cognitive domain T-scores, adjusting for age, showed that worse performance in visual-spatial memory tasks was associated with higher V_T in the precuneus and the entire parietal cortex.</p><p><strong>Conclusions: </strong>Higher α4β2-nAChR binding in posterior cortical regions is found in PD and associated with worse visual perception and memory, possibly due to lower receptor occupancy by endogenous acetylcholine.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X241313373"},"PeriodicalIF":4.0,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to advance the pharmacological management of cognitive impairment in Parkinson's disease.","authors":"Carla Abdelnour, Lucy L Gibson, Lucia Batzu, Dag Aarsland","doi":"10.1177/1877718X251315645","DOIUrl":"https://doi.org/10.1177/1877718X251315645","url":null,"abstract":"<p><p>Cognitive impairment is a common non-motor symptom in people with Parkinson's disease (PD) and is associated to poor clinical outcomes. Currently, rivastigmine is the only approved medication for PD dementia, and there are no treatments available for people with PD and mild cognitive impairment. To advance the pharmacological management of cognitive impairment in PD, it is essential to optimize clinical trial design. This includes refining cognitive outcome measures, ensuring longer study durations, and incorporating PD-specific cognitive assessments. Biomarkers offer valuable opportunities for screening, stratification, enrichment, and monitoring in trials, increasing the likelihood of detecting treatment effects. Additionally, adopting patient-centered approaches that prioritize inclusivity can enhance trial validity and address the current lack of diversity in PD studies. Digital cognitive assessments offer a promising tool for improving participation and enabling longitudinal monitoring, especially in underrepresented and mobility-challenged populations. By tackling these challenges, this review outlines strategies for advancing the pharmacological management of cognitive impairment in PD. It emphasizes the need for precise, inclusive, and biomarker-driven trials to accelerate drug development.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X251315645"},"PeriodicalIF":4.0,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aging, cellular senescence and Parkinson's disease.","authors":"Yue Ma, Madalynn L Erb, Darren J Moore","doi":"10.1177/1877718X251316552","DOIUrl":"https://doi.org/10.1177/1877718X251316552","url":null,"abstract":"<p><p>Parkinson's disease (PD) is the most common neurodegenerative movement disorder, affecting 1-2% of people over age 65. The risk of developing PD dramatically increases with advanced age, indicating that aging is likely a driving factor in PD neuropathogenesis. Several age-associated biological changes are also hallmarks of PD neuropathology, including mitochondrial dysfunction, oxidative stress, and neuroinflammation. Accumulation of senescent cells is an important feature of aging that contributes to age-related diseases. How age-related cellular senescence affects brain health and whether this phenomenon contributes to neuropathogenesis in PD is not yet fully understood. In this review, we highlight hallmarks of aging, including mitochondrial dysfunction, loss of proteostasis, genomic instability and telomere attrition in relation to well established PD neuropathological pathways. We then discuss the hallmarks of cellular senescence in the context of neuroscience and review studies that directly examine cellular senescence in PD. Studying senescence in PD presents challenges and holds promise for advancing our understanding of disease mechanisms, which could contribute to the development of effective disease-modifying therapeutics. Targeting senescent cells or modulating the senescence-associated secretory phenotype (SASP) in PD requires a comprehensive understanding of the complex relationship between PD pathogenesis and cellular senescence.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X251316552"},"PeriodicalIF":4.0,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}